Lannett Starts Trial For Lantus Rival With HEC

 
• By Dave Wallace

Lannett has announced the start of an initial clinical trial in South Africa for the insulin glargine biosimilar it is developing with HEC for the US market.

Clinical trial
A Clinical Trial For Lannett And HEC’s Insulin Glargine Has Been Initiated • Source: Shutterstock

More from Biosimilars

More from Products